Thyroid tablets recalled for subpotency
- PDF / 150,952 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 81 Downloads / 155 Views
1
Thyroid tablets recalled for subpotency Two lots of thyroid tablets containing levothyroxine (T4) and liothyronine (T3) have been voluntarily recalled by the manufacturer Acella Pharmaceuticals, LLC, to the consumer level. The company announcement, dated 17 September 2020 and posted on the same day by the US FDA, was made because testing revealed one lot of 15-mg and one lot of 120-mg NP Thyroid® to be subpotent. The products may contain as little as 87% of the labelled amount of levothyroxine (T4). These lots were distributed nationwide in the US. Acella is notifying its wholesalers to discontinue distribution of the two lots that are being recalled. The return of all recalled products is being arranged. Patients who are currently taking these subpotent drug products should not discontinue use and are advised to contact their healthcare provider. FDA. Acella Pharmaceuticals, LLC Issues Voluntary Nationwide Recall of Two Lots of NP Thyroid, Thyroid Tablets, USP Due to Sub Potency. Internet Document : 17 Sep 2020. Available from: URL: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/acella-pharmaceuticals-llc-issues-voluntary-nationwide-recall-two-lots-np803504363 thyroidr-thyroid-tablets
0114-9954/20/1823-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 26 Sep 2020 No. 1823
Data Loading...
